Rational Pharmacotherapy in Cardiology最新文献

筛选
英文 中文
Effectiveness of Class IC Antiarrhythmics in Patients with Paroxysmal Form of Atrial Fibrillation in Absence of Structural Heart Disease IC类抗心律失常药物对无结构性心脏病的阵发性心房颤动患者的疗效
IF 0.2
Rational Pharmacotherapy in Cardiology Pub Date : 2023-04-28 DOI: 10.20996/1819-6446-2023-03-09
D. Tsaregorodtsev, M. A. Khalikova, S. S. Vasyukov, M. Beraya, A. V. Sedov
{"title":"Effectiveness of Class IC Antiarrhythmics in Patients with Paroxysmal Form of Atrial Fibrillation in Absence of Structural Heart Disease","authors":"D. Tsaregorodtsev, M. A. Khalikova, S. S. Vasyukov, M. Beraya, A. V. Sedov","doi":"10.20996/1819-6446-2023-03-09","DOIUrl":"https://doi.org/10.20996/1819-6446-2023-03-09","url":null,"abstract":"Aim. To study the efficacy of class IC arrhythmic drugs (AAD) and catheter ablation (CA) for paroxysmal form of atrial fibrillation (AF) in patients with without structural heart disease.Material and methods. The study included 122 patients (44 men, 78 women, mean age 63 [55;68] years) with symptomatic AF paroxysms. Patients was divided into the lappaconitine hydrobromide group (LH group; n=26), the propafenone group (P group; n=25) – 25 patients, the diethylaminopropionylethoxycarbonylaminophenothiazine hydrochloride (DH group; n=23), the CA groups: radiofrequency ablation (RFA group; n=24) and cryoballoon ablation (CRYO group; n=24) groups each included 24 patients. The primary endpoint was the AF recurrence within 6 and 12 months from the onset of antiarrhythmic drug therapyand in RFA and CRYO groups – within 6 and 12 months after the end of the blinding period. Additionally, in AAD groups a composite endpoint was assessed: the frequency of recurrence of AF within 6 months and the frequency of side effects requiring drug withdrawal.Results. Within the 6 months AF recurrence was observed in 13 (50%) patients of the LH group, 11 (44%) patients of the P group, and 13 (56.5%) patients of the DH group (p=0.687). Side effects requiring drug withdrawal were observed in the LH group in 2 patients (7.7%), in the P group in 3 patients (12%) and in the DH group in 3 patients (13%) (p=0.801). The difference in frequency of reaching the composite endpoint was not significant (p = 0.581) and the incidence was 57.7%, 56%, 69.5%, respectively in groups LH, P and DH. The efficacy of CA was higher than class IC AADs: 77% vs 39% (that including the withdrawals of AADs due to side effects) (p˂0.001). At the same time, there was no significant difference in the effectiveness of RFA and CRYO: AF recurrences within 6 months after the end of the blinding period were registered in the RFA group in 29% of cases, in the CRYO group – in 16.7% of cases (p=0.247). The overall effectiveness of CA after 12 months was 69%, which was significantly higher than the effectiveness of AADs that was 38% (p˂0.001).Conclusion. Starting the AAD therapy with IC class in patients with paroxysmal AF in the absence of structural pathology, despite acceptable safety, one should take into account that, regardless of the initially prescribed drug, less than half of patients can achieve prevention of AF recurrence within 1 year. CA for AF can be considered as a first line therapy or can be recommended if one of IC class AADs is ineffective. ","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"11 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90925113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evolution of CHA2DS2-VASc Score for Predicting Risk of Stroke Development in Patients with Atrial Fibrillation 房颤患者CHA2DS2-VASc评分预测卒中发生风险的演变
IF 0.2
Rational Pharmacotherapy in Cardiology Pub Date : 2023-04-28 DOI: 10.20996/1819-6446-2023-03-05
A. Rubanenko
{"title":"Evolution of CHA2DS2-VASc Score for Predicting Risk of Stroke Development in Patients with Atrial Fibrillation","authors":"A. Rubanenko","doi":"10.20996/1819-6446-2023-03-05","DOIUrl":"https://doi.org/10.20996/1819-6446-2023-03-05","url":null,"abstract":"Atrial fibrillation (AF) is associated with dramatic increasing of stroke risk. Development of this serious complication is accompanied by high mortality and disability. Nowadays we know many different scores that predict stroke risk,butthe most popular is CHA2DS2-VASc risk score. At the same time, this score does not have high predictive accuracyand that is why a lot of modifications with inclusion/deletion of different indicators were introduced.The aim of this review was to estimate the different modifications of CHADS2 и CHA2DS2-VASc scores in predicting stroke risk in patients with AF. In this review R2CHADS2, CHA2DS2-VASc-R, CHA2DS2-VA, mCHA2DS2-VASc and CHA2DS2-VAK scores are evaluated with the use of C-statistics and net reclassification index compared to the original CHA2DS2-VASc score. The search of studies was performed according to PubMed database (https://pubmed.ncbi.nlm.nih.gov/) from 2011 until 2021 years. In this review were included studies written in English with free full text. Literature reviews, books, abstracts books, studies performed on less than 900 patients and studies without C-statistics data available were excluded from this review. Despite of the numerous attempts to improve the quality of CHA2DS2-VASc score, existing modifications nowadays could not become more popular in clinical practice. At the same time, developing of the new score systems, that will have better predictive values in stroke prognosis than CHA2DS2-VASc score, is still an actual problem in modern cardiology. ","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"46 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89948293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Effect of Antibiotic Therapy on the Sensitivity of Etiological Diagnostic Methods in Patients with Infective Endocarditis after Surgery 抗生素治疗对感染性心内膜炎术后病因诊断方法敏感性的影响
IF 0.2
Rational Pharmacotherapy in Cardiology Pub Date : 2023-03-07 DOI: 10.20996/1819-6446-2023-02-03
E. Kotova, A. Moiseeva, Z. Kobalava, E. Domonova, A. S. Pisaruk, O. Y. Silveistrova, P. V. Kakhktsyan, V. Vladimirov
{"title":"Effect of Antibiotic Therapy on the Sensitivity of Etiological Diagnostic Methods in Patients with Infective Endocarditis after Surgery","authors":"E. Kotova, A. Moiseeva, Z. Kobalava, E. Domonova, A. S. Pisaruk, O. Y. Silveistrova, P. V. Kakhktsyan, V. Vladimirov","doi":"10.20996/1819-6446-2023-02-03","DOIUrl":"https://doi.org/10.20996/1819-6446-2023-02-03","url":null,"abstract":"Aim. Assessment of impact  of the duration  of preoperative  antimicrobial  therapy  (AMT) on the sensitivity  of microbiological examination and polymerase  chain reaction (PCR) of blood/tissues of resected valves in operated patients with infective endocarditis  (IE).Materials and methods. 52 operated patients with active IE were included prospectively (Duke criteria, 2015). All patients underwent microbiological examination of blood  before  admission  to the cardiac  surgery  hospital,  as well as parallel  simultaneous microbiological examination and  PCR  of blood/tissues of excised  valves,  followed  by Sanger  sequencing. The duration  of preoperative  treatment  was  calculated  from the first day of AMT according to IE diagnosis to the day of surgery.Results. The causative agent of IE was established in 84.6% (n=44) patients by means of complex etiological diagnosis. A significant  decrease in the sensitivity of microbiological examination of venous blood was revealed when performed  in the period before and after hospitalization to a surgical hospital (up 44.2% to 17.3%, p<0.05). When comparing microbiological examination of blood/tissues of resected valves and PCR of blood/tissues of resected valves, molecular biological  methods demonstrated the greatest sensitivity, with a great advantage when examining the tissues of resected valves (17.3% and 19.2% vs. 38.5% and 75.0%, respectively;  p<0.001). The microbiological examination of venous blood performed  at an early date before admission  to the cardiac  surgery  hospital was comparable in sensitivity to the PCR blood test performed  at a later date after prolonged AMT,  and significantly less sensitive in relation to the PCR of resected valve tissues [44.2% and 38.5% (p>0.05) vs. 75.0% (p<0.05)]. In course of AMT 1-28 days,  there were comparable results of microbiological examination with PCR blood examination and significantly better results of PCR of resected valve tissues [31.0% and 34.5% and 41.4% (p>0.05) vs 72.4% (p<0.001), respectively], and with AMT ≥ 29 days, microbiological examination of any biological  material was negative  in all patients,  and PCR of blood/tissues of resected valves retained high sensitivity (0% and 0% vs. 34.8% and 78.3%, respectively; p<0.01).Conclusion. Long-term preoperative AMT significantly reduced the sensitivity of microbiological examination of resected valve blood/tissue in operated patients with IE, whereas PCR of resected valve blood/tissue was highly sensitive even with preoperative AMT for more than 29 days.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"73 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86256778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chronic Heart Failure and Pulmonary Hypertension: Difficulties in Assessment of Prognosis and Potential Solutions 慢性心力衰竭和肺动脉高压:评估预后的困难和潜在的解决办法
IF 0.2
Rational Pharmacotherapy in Cardiology Pub Date : 2023-03-07 DOI: 10.20996/1819-6446-2023-01-01
V. A. Mareyeva, A. Klimenko, N. Shostak
{"title":"Chronic Heart Failure and Pulmonary Hypertension: Difficulties in Assessment of Prognosis and Potential Solutions","authors":"V. A. Mareyeva, A. Klimenko, N. Shostak","doi":"10.20996/1819-6446-2023-01-01","DOIUrl":"https://doi.org/10.20996/1819-6446-2023-01-01","url":null,"abstract":"Pulmonary  hypertension  and  right  heart dysfunction often  complicate  the course  of chronic  heart failure.  At the same  time,  the addition  of these pathological conditions  significantly increases the frequency  of hospitalizations and worsens survival prognosis. That is why the assessment  of the unfavorable outcome’s risk in the group of such patients is extremely important. This problem draws an interest for a more detailed study, considering the fact that the most convenient,  accessible and minimally invasive prognosis marker has still being searched for nowadays. In this review article, which is based on the analysis of literature over the past 20 years dedicated to the problem of pulmonary hypertension  and chronic heart failure, right ventricular-arterial  coupling, has been considered  as a relatively new parameter  and as an example  of one of these prognostic markers.  This parameter  can be assessed  by echocardiography  examination and  our article describes  several  options  of calculating it, including  one of the most  popular  and valuable ratio of tricuspidal anular plane systolic excursion to the systolic pulmonary artery pressure (TAPSE/sPAP).","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"59 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72711256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Study of Adherence to Drug Therapy at the Stage of Outpatient Follow-up in Patients with Acute Myocardial Infarction (Data from the PROFIL-IM Registry) 急性心肌梗死患者门诊随访阶段药物治疗依从性的研究(数据来自PROFIL-IM登记)
IF 0.2
Rational Pharmacotherapy in Cardiology Pub Date : 2023-03-07 DOI: 10.20996/1819-6446-2023-02-04
E. P. Kalaydzhyan, N. Kutishenko, Y. Lukina, D. P. Sichinava, S. Martsevich, O. Drapkina
{"title":"The Study of Adherence to Drug Therapy at the Stage of Outpatient Follow-up in Patients with Acute Myocardial Infarction (Data from the PROFIL-IM Registry)","authors":"E. P. Kalaydzhyan, N. Kutishenko, Y. Lukina, D. P. Sichinava, S. Martsevich, O. Drapkina","doi":"10.20996/1819-6446-2023-02-04","DOIUrl":"https://doi.org/10.20996/1819-6446-2023-02-04","url":null,"abstract":"Aim. To assess adherence  to the recommended therapy at the stage of outpatient follow-up and its impact on long-term outcomes  in patients after acute myocardial  infarction based on the materials of the prospective PROFILE-IM registry.Material and methods. The PROFILE-IM register included 160 patients who applied to one of the polyclinics in Moscow after a myocardial  infarction. The combined endpoint (CE) included death from any cause, cardiovascular events (nonfatal myocardial infarction,  nonfatal cerebral stroke), emergency hospitalizations for cardiovascular diseases, significant  cardiac arrhythmias. Patients' adherence to therapy was assessed using the original questionnaire \"Scale of Adherence of the National Society of Evidence-based Pharmacotherapy\" (NODF) and a direct standardized patient survey by a doctor about taking medications. Visits to the doctor were carried out every two months,  data from the first year of patient follow-up are presented.Results. In a personal  interview  with a doctor,  the ratio of the proportion  of committed, partially  committed  and non-committed patients  did not change  significantly over the entire follow-up period, while the proportion of committed patients was 81-85%. The \"NODF Adherence Scale\" showed that the proportion of non-committed patients was about 10 times higher than with direct patient responses to the doctor, and the proportion of non-committed  and partially committed  patients remained high at all stages of follow-up (respectively 28% and 10% at the beginning of the study, 18% and 10% at the end of the study).  Among the main factors  of non-commitment, there was a decrease  in the importance  of forgetfulness and an increase  in factors  such  as fear  of side effects  of medications, doubt  about  the need  for long-term use of medications  and  well-being. A  direct relationship of adherence with the male sex, the presence of hypertension, a feedback  relationship with alcohol consumption was revealed. The risk of CE in non-committed patients was higher compared  to the group of committed  and partially committed  patients (p<0.01).Conclusion. The proportion of non-committed and partially committed patients remained high at all stages of follow-up. There was a direct relationship between adherence to therapy with the male sex, the presence of hypertension in the anamnesis, and a feedback relationship with alcohol consumption. Low adherence to therapy significantly increased the risk of cardiovascular events.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"36 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90088182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of The Use of PCSK9 Inhibitors in Clinical Practice PCSK9抑制剂在临床中的应用分析
IF 0.2
Rational Pharmacotherapy in Cardiology Pub Date : 2023-03-07 DOI: 10.20996/1819-6446-2023-02-01
S. Y. Volkova, L. A. Boyarskaya, P. Y. Toropygin, I. Morozov, E. A. Boyarskaya
{"title":"Analysis of The Use of PCSK9 Inhibitors in Clinical Practice","authors":"S. Y. Volkova, L. A. Boyarskaya, P. Y. Toropygin, I. Morozov, E. A. Boyarskaya","doi":"10.20996/1819-6446-2023-02-01","DOIUrl":"https://doi.org/10.20996/1819-6446-2023-02-01","url":null,"abstract":"Aim. The analysis of the experience of using PCSK9 inhibitors (alirocumab) in patients with very high cardiovascular risk, аccording to long observations in real clinical practice.Material and methods. In study evaluated the data for 31  people (23 men and 8 women, the average  age of those surveyed was 59.4±5.8 years) of very high cardiovascular risk with atherogenic dyslipidemia  and no achievement  of the target lipid levels. Alirokumab was administered  in a dose of 150 mg subcutaneously once every 2 weeks in the day hospital of a multidisciplinary clinic. The primary endpoint was reached the target level of low density lipoprotein cholesterol (HS-LDL) level and/or reduce HS-LDL levels by 50% or more. Liver tests, level of creatinine and glycemia  were studied to assess safety; side effects studied/Results. The long-term use of alirocumab  (on average 7,5±2,3 months) is well tolerated without adverse reactions and withdrawal syndrome, in the day hospital of a multidisciplinary clinic. 90% of patient have achieved either a target level of HS-LDL less than 1.4 mmol/l or a reduction in HS-LDL by 50% or more. The remaining  third of patients achieved both target levels. It can be distinguished a group of patients with a good response to the medication, in the first months of administration of alirokumab.Conclusion. The results of conducting an efficiency  assessment  for use of the alirocumab  in a dose of 150 mg  subcutaneously within two weeks showed  that this therapy has the high efficacy and good tolerability without any adverse reactions,  in the day hospital of a multidisciplinary clinic.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"30 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77764982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence and Severity of Acute Myocardial Injury after Thoracic Surgery: Effects of Nicorandil 胸外科术后急性心肌损伤的发生率和严重程度:尼可地尔的影响
IF 0.2
Rational Pharmacotherapy in Cardiology Pub Date : 2023-03-07 DOI: 10.20996/1819-6446-2023-01-08
K. Protasov, O. A. Barahtenko, E. Batunova, E. A. Rasputina
{"title":"Incidence and Severity of Acute Myocardial Injury after Thoracic Surgery: Effects of Nicorandil","authors":"K. Protasov, O. A. Barahtenko, E. Batunova, E. A. Rasputina","doi":"10.20996/1819-6446-2023-01-08","DOIUrl":"https://doi.org/10.20996/1819-6446-2023-01-08","url":null,"abstract":"Aim. To study the perioperative dynamics of myocardial injury biomarkers high-sensitivity cardiac troponin I (hs-cTnI), ischemia-modified albumin (IMA) and soluble ST2 (sST2) when taking nicorandil in lung cancer patients with concomitant coronary heart disease (CHD) undergoing surgical lung resection.Material and methods. The study included 54 patients (11 women and 43 men) with non-small cell lung cancer and concomitant stable CHD who underwent lung resection in the volume of lobectomy or pneumonectomy. Patients were randomly assigned to the nicorandil group (oral administration 10 mg BID for 7 days before and 3 days after surgery; n=27) and the control group (n=27). In the study groups, the perioperative dynamics of hscTnI, IMA and sST2, determined in the blood before and 24 and 48h after surgery, were compared. We calculated the incidence of acute myocardial injury in the groups, which was diagnosed in cases of postoperative hs-cTnI increase of more than one 99th percentile of the upper reference limit. The associations of nicorandil intake and acute myocardial injury were evaluated.Results. The groups were comparable in gender, age, basic clinical characteristics, as well as baseline levels of myocardial injury biomarkers. After the intervention, both samples showed an increase in the hs-cTnI and sST2 levels and a decrease in IMA concentration (all p<0.02 for related group differences). In the nicorandil group, in comparison with the control one, 48h after surgery, we found lower mean levels of hs-cTnI [16.7 (11.9;39.7) vs 44.3 (15.0;130.7) ng/l; p<0.05) and sST2 [62.8 (43.6;70.1) vs 76.5 (50.2;87.1) ng/ml; p<0.05), concentration increase rates of hs-cTnI [14.8 (0.7;42.2) vs 32.5 (14.0;125.0) ng/l; p<0.01) and sST2 [24.4 (10.3;42.4) vs 47.4 (17.5;65.3) ng/ml; p<0.05), as well as highest concentrations for the entire postoperative period of hs-cTnI [30.7 (12.0;53.7) vs 79.0 (20.3;203.3) ng/L, p<0.01] and sST2 [99.8 (73.6;162.5) vs 147.8 (87.8;207.7) ng/mL; p<0.05]. The serum IMA decreased when taking nicorandil to a greater extent [-8.0 (-12.6; -2.0) vs -2.7 (-6.0; +5.5) ng/ ml; p<0.01] 24h after surgery. Acute myocardial injury was diagnosed in 7 people in the nicorandil group (25.9%) and in 15 in the control one (55.6%; pχ2=0.027). The adjusted odds ratio of acute myocardial injury when taking nicorandil was 0.35 (95% confidence interval 0.15-0.83, p=0.017).Conclusion. Taking  nicorandil  in patients with lung cancer and concomitant CHD  who underwent  surgical  lung resection is associated  with a lower postoperative  increase in hs-cTnI  and sST2  and a reduced risk of acute myocardial  injury, which may indicate the cardioprotective effect of nicorandil under acute surgical stress conditions.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"31 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84207674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Arrhythmic Mitral Valve Prolapse: New Menaces of the Known Disease 心律失常二尖瓣脱垂:已知疾病的新威胁
IF 0.2
Rational Pharmacotherapy in Cardiology Pub Date : 2023-03-07 DOI: 10.20996/1819-6446-2023-01-05
D. A. Kuzhel, G. V. Matyushin, E. Savchenko
{"title":"Arrhythmic Mitral Valve Prolapse: New Menaces of the Known Disease","authors":"D. A. Kuzhel, G. V. Matyushin, E. Savchenko","doi":"10.20996/1819-6446-2023-01-05","DOIUrl":"https://doi.org/10.20996/1819-6446-2023-01-05","url":null,"abstract":"Mitral  valve prolapse  (MVP) has  long  been  the subject  of intense  discussions regarding the prognosis and  follow-up tactics.  In most  cases,  this condition has a benign prognosis. However, recent autopsy and follow-up studies have shown risks of developing  sudden cardiac death (SCD) in some subgroups of patients who have this clinical phenomenon. The proposed  literature review uses the population  of patients with MVP with the highest probability  of developing  life-threatening ventricular tachyarrhythmias. Patients with the presence of a complex  of changes, including  bicuspid  MVP, negative T waves in the inferior and lateral leads on a standard  12-lead electrocardiogram (ECG), and a special anatomical  phenomenon called mitral annular  disjunction  (MAD), are at high  risk of developing  ventricular  ectopias  and VSS.  A reflection  of the high  risk of SCD  in such patients  is the increase of ventricular ectopy according to Holter monitoring. The presence of a bicuspid  MVP and the MAD  phenomenon, which is a separation  of the line of attachment  of the posterior mitral leaflet from the basal inferior wall segment  towards  the atrial wall, determines the presence of a special form of MVP,  the so-called  arrhythmogenic MVP.  Hence,  in most cases MVP has a benign  prognosis. However, patients with the aforementioned ar- rhythmic  MVP  signs  must  be given  particular  attention  and  annual  follow-up including  ECG  control,  Holter  monitoring and  echocardiographic examination of the heart to reduce the risk of ventricular tachyarrhythmias and SCD development.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"106 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87874227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Case of Successful Medical Treatment of Ventricular Tachycardia in a Patient With Ischemic Heart Disease and Heart Failure 缺血性心脏病合并心力衰竭患者室性心动过速医学治疗成功一例
IF 0.2
Rational Pharmacotherapy in Cardiology Pub Date : 2023-03-07 DOI: 10.20996/1819-6446-2023-02-05
E. Ryngach, A. Tatarinova, E. Zhabina, O. N. Zhdanova, T. Treshkur
{"title":"A Case of Successful Medical Treatment of Ventricular Tachycardia in a Patient With Ischemic Heart Disease and Heart Failure","authors":"E. Ryngach, A. Tatarinova, E. Zhabina, O. N. Zhdanova, T. Treshkur","doi":"10.20996/1819-6446-2023-02-05","DOIUrl":"https://doi.org/10.20996/1819-6446-2023-02-05","url":null,"abstract":"The pathogenetic mechanisms of arrhythmias, including  high-grade ventricular  arrhythmias (including non-sustained ventricular  tachycardia),  in patients with coronary  heart disease may be different. Therefore, the characteristics  of ventricular arrhythmias must be considered  based on the totality of data, taking  into account all the available features. The importance  of a personalized approach  to the management of a patient with coronary  heart disease who had extensive myocardial  infarction 18.5 years ago,  followed  by mammary  coronary  artery bypass  grafting, aneurysmectomy and the development of heart failure with a low ejection fraction, in whom ventricular arrhythmias occurred against the background of a stable course of coronary disease , but after emotional stress, is reflected in this work. An extended examination, as well as a detailed study of the nature of ventricular arrhythmias, made it possible  to determine  the main provoking factor and select an individualized pathogenetic treatment with a good  antiarrhythmic result that persists for several years of observation.  Conducting mental tests and psychological questioning can be recommended for patients with coronary  heart disease  and  chronic  heart failure as an additional  examination to assess  the contribution  of the psycho-emotional factor  to arrhythmogenesis after excluding the ischemic and sympathetic  nature of ventricular ectopia. It is incorrect to consider that all ventricular arrhythmias  in patients with coronary heart disease are ischemic in nature, and in some clinical situations this statement is even erroneous.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89688312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relief of persistent atypical atrial flutter: experience with the use of niferidil 缓解持续不典型心房扑动:使用硝呋地尔的经验
IF 0.2
Rational Pharmacotherapy in Cardiology Pub Date : 2023-03-07 DOI: 10.20996/1819-6446-2023-01-07
E. A. Zakharyan, D. V. Shatov, A. O. Povoroznyj, T. B. Bujar
{"title":"Relief of persistent atypical atrial flutter: experience with the use of niferidil","authors":"E. A. Zakharyan, D. V. Shatov, A. O. Povoroznyj, T. B. Bujar","doi":"10.20996/1819-6446-2023-01-07","DOIUrl":"https://doi.org/10.20996/1819-6446-2023-01-07","url":null,"abstract":"An increase in life expectancy contributes to a steady growth  of diseases of the cardiovascular system. In recent years, there has been a stable increase in the prevalence  of rhythm  disturbances  in the population.  Fibrillation and atrial flutter are among  the most common  causes  of a decrease  in the quality of life and an increase in mortality. However, the effectiveness  of various methods of treatment is not absolute,  and therefore the development and introduction  of new antiarrhythmic drugs  is particularly  relevant. Thus,  the use of a class III antiarrhythmic drug  (niferidil) is of unconditional interest, and literature data describing the effectiveness  of its use for the relief of atypical atrial flutter are extremely few. The article presents a case of successful  relief of a persistent form of atypical atrial flutter in a 79-year-old patient using three consecutive intravenous injections of niferidil at a dose of 10 mcg/kg with a 15-minute interval in 19 hours after the start of therapy. The presented clinical case confirms the effectiveness of drug cardioversion with the use of niferidil and makes it possible to consider it as an alternative to electrical cardioversion  in patients with atypical atrial flutter.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"63 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77774657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信